818 results on '"Hebert, Adelaide A."'
Search Results
202. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP nonsteroidal cream in the management of mild to moderate atopic dermatitis in infants and children: P705
203. Insect repellents: Historical perspectives and new developments: P550
204. Evaluation of Adrenal Suppression of a Lipid Enhanced, Topical Emollient Cream Formulation of Hydrocortisone Butyrate 0.1% in Treating Children with Atopic Dermatitis
205. TOPICAL FLUTICASONE PROPIONATE LOTION DOES NOT CAUSE HPA AXIS SUPPRESSION
206. Patients previously well controlled with pimecrolimus cream 1% and pulses of midpotent topical corticosteroids experienced severe exacerbation of atopic dermatitis upon discontinuation of treatment: P2531
207. Periorbital cellulitis in the pediatric population: P2515
208. A multicenter randomized, vehicle-controlled, double-blind clinical study to examine the safety and efficacy of MAS063DP in the management of AD: P818
209. Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne
210. FURTHER EVIDENCE OF THE SAFETY OF TOPICAL FLUTICASONE PROPIONATE: UNDER EXAGGERATED CONDITIONS OF USE, A NEW EMULSION PREPARATION HAS NO EFFECT ON HPA-AXIS FUNCTION: P718
211. COMBINATION OF DESOXIMETASONE 0.25% AND TACROLIMUS 0.1% OINTMENTS FOR THE TREATMENT OF ATOPIC DERMATITIS: P706
212. AN OPEN-LABEL ADRENAL SUPPRESSION STUDY OF HYDROCORTISONE BUTYRATE 0.1% LIPOCREAM USED THREE TIMES DAILY IN CHILDREN 5 TO 12 YEARS OLD WITH MODERATE TO SEVERE ECZEMA OR ATOPIC DERMATITIS: P702
213. Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome
214. Neurothekeoma: Report of a case in an infant and review of the literature
215. A Novel GJB2 (Connexin 26) Mutation, F142L, in a Patient with Unusual Mucocutaneous Findings and Deafness
216. Multiple Bilateral Vesiculobullous Lesions on the Lower Extremities
217. 100 - Hemangiomas
218. Neonatal Primary Cutaneous Aspergillosis: Case Report and Review of the Literature
219. Nonendemic pemphigus foliaceus in children
220. Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine
221. Benign Cutaneous Vascular Tumors of Infancy: When to Worry, What to Do
222. List of Contributors
223. Patient impact and economic burden of mild to moderate atopic dermatitis
224. Sodium hypochlorite body wash in the management ofStaphylococcus aureus–colonized moderate‐to‐severe atopic dermatitis in infants, children, and adolescents
225. A Phase 1 Open -Label Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005% Applied Under Maximal Use Conditions in Adolescent Subjects with Plaque Psoriasis
226. Ozenoxacin: a review of preclinical and clinical efficacy
227. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials
228. Short- and Long-Term Efficacy and Safety of Glycopyrronium Cloth for the Treatment of Primary Axillary Hyperhidrosis: Post Hoc Pediatric Subgroup Analyses from the Phase 3 Studies
229. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials
230. A randomized trial to assess once-daily topical treatment of tinea corporis with butenafine, a new antifungal agent
231. Diagnosis and treatment of tinea capitis in children
232. A Progressive Blistering Eruption in a Patient With Lymphoma
233. Malignant Rhabdoid Tumor Presenting as a Hemangioma
234. Atopic dermatitis of infancy
235. Neonatal Pemphigus Foliaceus
236. Recognizing and Managing Staphylococcal Scalded Skin Syndrome in the Emergency Department.
237. Skin lesions of the spinal axis and spinal dysraphism
238. A comparative review of current topical antibiotics for impetigo
239. Recent Advances in the Treatment and Management of Moderate-to-Severe Atopic Dermatitis: What's New in Biologic Therapies.
240. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials
241. The case of the dog and the blue light
242. The cutaneous manifestations of tuberous sclerosis complex
243. Patient impact and economic burden of mild-to-moderate atopic dermatitis
244. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo
245. Crisaborole Ointment Effect on Global Atopic Dermatitis Severity and Early Relief in Pruritus: Pooled Results From Two Phase 3 Clinical Trials
246. Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry
247. Efficacy, Tolerability, and Safety of SB204 Gel in Adolescents (9 to 17 Years of Age) with Acne Vulgaris
248. Burden of Axillary Hyperhidrosis Using a Patient-Reported Outcome Measure to Assess Impact on Activities and Bothersomeness
249. Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Primary Axillary Hyperhydrosis
250. Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.